• Test Code:
  • Department:
  • Test Synonyms:
    Factor V LeidenHereditary Resistance Activated Protein C ResistanceResistance to Activated Protein CActivated protein C resistanceAPC resistanceFactor V R506QFCV
  • CPT Code(s):

Factor V Leiden thrombophilia is an inherited disorder of blood clotting.  Factor V Leiden is the name of a specific gene mutation that results in thrombophilia, which is an increased tendency to form abnormal blood clots that can block blood vessels.  Afflicted persons present with a history of venous thromboembolism (VTE) manifesting as deep vein thrombosis (DVT) or of pulmonary embolism, especially in women with a history of VTE during pregnancy (or in association with oral contraceptive use) and in persons  with a personal or family history of recurrent thrombosis.
A coagulation screening test or DNA analysis of the F5 gene can be used to diagnose factor V Leiden thrombophilia.  Factor V Leiden refers to the specific G-to-A substitution at nucleotide 1691 in the gene for factor V that predicts a single amino-acid replacement (R506Q) at one of three APC cleavage sites in the factor V(a) molecule1.


Polymerase chain reaction/Fluorescence monitoring.

Specimen Requirements:

Blood:  6.0 mL in EDTA (purple-top) or ACD (yellow-top) tube

DNA: 10ng at a minimum of 100ng/µL (DNA must be extracted in a CLIA-certified laboratory or a laboratory meeting equivalent requirements as determined by the CAP and/or CMS)

A REQUISITION FORM MUST ACCOMPANY ALL SAMPLES.  Please include detailed clinical information, including ethnicity, clinical history, and family history.

Test Performed (Days):


Turn Around Time:

7 – 10 Days

Shipment Sensitivity Requirements:

  • Keep specimen cold during transit, but do not ship on dry ice. 
  • Please use the cold pack provided in the KDL shipping kit. 
  • Contact Client Services at (855) 535-1522 for shipping kits and instructions. 
  • Ship the specimen overnight express, using the FedEx priority overnight label provided. 


  1. Kujovich, JL.  Factor V Leiden Thrombophilia. Gene Reviews.  http://www.ncbi.nlm.nih.gov/books/NBK1368/  Initial Posting: May 14, 1999; Last Update: March 9, 2010.

Additional Info:

PCR-based direct detection of codon 506 Factor V mutation causing resistance to activated protein C and familial thrombosis.  Call the lab at (855)535-1522 for more information.

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

Learn More